836 related articles for article (PubMed ID: 34360566)
1. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
[TBL] [Abstract][Full Text] [Related]
2. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
Liu X; Li S; Wang L; Ma K
Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167230. PubMed ID: 38734322
[TBL] [Abstract][Full Text] [Related]
3. Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study.
Li L; Ye J
Medicine (Baltimore); 2020 Sep; 99(37):e21788. PubMed ID: 32925716
[TBL] [Abstract][Full Text] [Related]
4. The Microbiome and Hepatocellular Carcinoma.
Rattan P; Minacapelli CD; Rustgi V
Liver Transpl; 2020 Oct; 26(10):1316-1327. PubMed ID: 32564483
[TBL] [Abstract][Full Text] [Related]
5. Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma.
Zhu C; Zhang C; Wang S; Xun Z; Zhang D; Lan Z; Zhang L; Chao J; Liang Y; Pu Z; Ning C; Sang X; Yang X; Wang H; Jiang X; Zhao H
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844407
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
Schwabe RF; Greten TF
J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.
Zheng Y; Wang T; Tu X; Huang Y; Zhang H; Tan D; Jiang W; Cai S; Zhao P; Song R; Li P; Qin N; Fang W
J Immunother Cancer; 2019 Jul; 7(1):193. PubMed ID: 31337439
[TBL] [Abstract][Full Text] [Related]
8. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
[TBL] [Abstract][Full Text] [Related]
10. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model.
Behary J; Raposo AE; Amorim NML; Zheng H; Gong L; McGovern E; Chen J; Liu K; Beretov J; Theocharous C; Jackson MT; Seet-Lee J; McCaughan GW; El-Omar EM; Zekry A
BMC Microbiol; 2021 Apr; 21(1):113. PubMed ID: 33858327
[TBL] [Abstract][Full Text] [Related]
11. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
Golonka RM; Vijay-Kumar M
Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota: A new piece in understanding hepatocarcinogenesis.
Zhou A; Tang L; Zeng S; Lei Y; Yang S; Tang B
Cancer Lett; 2020 Apr; 474():15-22. PubMed ID: 31917160
[TBL] [Abstract][Full Text] [Related]
13. Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.
Wu H; Zheng X; Pan T; Yang X; Chen X; Zhang B; Peng L; Xie C
Int J Cancer; 2022 Oct; 151(8):1321-1334. PubMed ID: 35579980
[TBL] [Abstract][Full Text] [Related]
14. The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection.
Yang R; Xu Y; Dai Z; Lin X; Wang H
J Immunol Res; 2018; 2018():2361963. PubMed ID: 30148173
[TBL] [Abstract][Full Text] [Related]
15. Beneficial Effect of Antibiotics and Microbial Metabolites on Expanded Vδ2Vγ9 T Cells in Hepatocellular Carcinoma Immunotherapy.
Han J; Zhang S; Xu Y; Pang Y; Zhang X; Hu Y; Chen H; Chen W; Zhang J; He W
Front Immunol; 2020; 11():1380. PubMed ID: 32849498
[TBL] [Abstract][Full Text] [Related]
16. Zn(II)-curcumin solid dispersion impairs hepatocellular carcinoma growth and enhances chemotherapy by modulating gut microbiota-mediated zinc homeostasis.
Wu R; Mei X; Ye Y; Xue T; Wang J; Sun W; Lin C; Xue R; Zhang J; Xu D
Pharmacol Res; 2019 Dec; 150():104454. PubMed ID: 31526871
[TBL] [Abstract][Full Text] [Related]
17. Toward a postbiotic era of microbiome science: Opportunities to advance immunotherapies for hepatocellular carcinoma.
Nakatsu G
J Gastroenterol Hepatol; 2022 Jan; 37(1):34-38. PubMed ID: 34665475
[TBL] [Abstract][Full Text] [Related]
18. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
[No Abstract] [Full Text] [Related]
19. Future prospect of "Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients".
Kang YB; Cai Y
World J Gastroenterol; 2022 May; 28(20):2248-2250. PubMed ID: 35721889
[TBL] [Abstract][Full Text] [Related]
20. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
